| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1040603226 |
| P356 | DOI | 10.2165/00148581-200507020-00001 |
| P698 | PubMed publication ID | 15871628 |
| P2093 | author name string | Raffaele Calabrò | |
| Fiorina Casale | |||
| Maria Teresa Di Tullio | |||
| Paolo Indolfi | |||
| Diana Iarussi | |||
| Vincenzo Martino | |||
| P2860 | cites work | Altered left ventricular mechanics in patients with valvular aortic stenosis and coarction of the aorta: effects on systolic performance and late outcome | Q93594383 |
| The anthracyclines: will we ever find a better doxorubicin? | Q28184842 | ||
| The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia | Q28271441 | ||
| ICRF-187 permits longer treatment with doxorubicin in women with breast cancer | Q28324350 | ||
| A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors | Q28327605 | ||
| Risk factors for doxorubicin-induced congestive heart failure | Q28328220 | ||
| Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation | Q28332981 | ||
| Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood | Q28334880 | ||
| Long term doxorubicin cardiotoxicity in childhood: non-invasive evaluation of the contractile state and diastolic filling | Q28361151 | ||
| Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 | ||
| Beta-blockade in adriamycin-induced cardiomyopathy | Q31412678 | ||
| Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease | Q33613318 | ||
| Overview of the management of pediatric heart failure | Q34026094 | ||
| Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia | Q34205638 | ||
| A clinicopathologic analysis of adriamycin cardiotoxicity | Q34207498 | ||
| Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. | Q34429779 | ||
| beta-Blocker therapy in heart failure: scientific review | Q34535956 | ||
| Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure | Q34620874 | ||
| Early anthracycline cardiotoxicity | Q34714914 | ||
| Early identification of anthracycline cardiomyopathy: possibilities and implications | Q34800157 | ||
| Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure? | Q34996538 | ||
| Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review | Q35686264 | ||
| Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology | Q36817729 | ||
| Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma | Q38573068 | ||
| Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy | Q39467426 | ||
| Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue | Q39499699 | ||
| The Neurohumoral Axis in Congestive Heart Failure | Q40094897 | ||
| The anthracycline antineoplastic drugs | Q40308244 | ||
| Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity | Q40827062 | ||
| Oral idarubicin--an anthracycline derivative with unique properties | Q40874693 | ||
| Clinical pharmacokinetics of idarubicin | Q40905930 | ||
| Cardiac toxicity 4 to 20 years after completing anthracycline therapy | Q41142694 | ||
| Peripartum heart failure in a patient treated previously with doxorubicin | Q42209663 | ||
| Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases | Q42218136 | ||
| Acute arrhythmogenicity of doxorubicin administration | Q42219140 | ||
| A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer | Q42224609 | ||
| Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. | Q42279363 | ||
| Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect | Q42280040 | ||
| Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients | Q42280268 | ||
| Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin | Q42556370 | ||
| Heart transplantation in a child with doxorubicin-induced cardiomyopathy | Q42676483 | ||
| The impact of childhood cancer on the United States and the world | Q43489405 | ||
| Carvedilol as therapy in pediatric heart failure: an initial multicenter experience | Q43570411 | ||
| 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology | Q44028634 | ||
| The Pediatric Randomized Carvedilol Trial in Children with Heart Failure: rationale and design | Q44135194 | ||
| Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer | Q44231142 | ||
| Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment | Q44244540 | ||
| Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines | Q44780572 | ||
| Biventricular heart failure in patient treated with anthracycline in childhood: myocardial dysfunction is not always the cause | Q44927860 | ||
| Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors | Q45933926 | ||
| ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary | Q58975486 | ||
| Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group | Q68114949 | ||
| Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer | Q68694142 | ||
| Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer | Q68756485 | ||
| The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy | Q70618512 | ||
| Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic index | Q71092978 | ||
| Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids | Q71581719 | ||
| Differences in dose scheduling as a factor in the etiology of anthracycline-induced cardiotoxicity in Ewing sarcoma patients | Q71848092 | ||
| Left ventricular end-systolic wall stress-velocity of fiber shortening relation: a load-independent index of myocardial contractility | Q72745852 | ||
| Cardiovascular abnormalities in long-term survivors of childhood malignancy | Q72790314 | ||
| Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure | Q73155607 | ||
| Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique | Q73719725 | ||
| Comparison of left ventricular function by echocardiogram in patients with Wilms' tumor treated with anthracyclines versus those not so treated | Q73727677 | ||
| Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas | Q74082946 | ||
| Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhood | Q74607086 | ||
| Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane | Q77398822 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 67-76 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Pediatric Drugs | Q15767256 |
| P1476 | title | Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management | |
| P478 | volume | 7 |
| Q40233201 | A precise pharmacodynamic study showing the advantage of a marked reduction in cardiotoxicity in continuous infusion of doxorubicin |
| Q48357803 | An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines. |
| Q46171847 | Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model. |
| Q36845348 | Cardiotoxicity of anthracycline therapy: current perspectives |
| Q37279228 | Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q |
| Q30491590 | Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography |
| Q50140943 | Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial |
| Q42835421 | Effect of telmisartan in limiting the cardiotoxic effect of daunorubicin in rats |
| Q90524204 | Erythrocytes as Carriers: From Drug Delivery to Biosensors |
| Q21135010 | Flavaglines alleviate doxorubicin cardiotoxicity: implication of Hsp27 |
| Q42157055 | Hemodynamic and biochemical alterations in dogs with lymphoma after induction of chemotherapy. |
| Q80078439 | Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of |
| Q86344610 | Intensified home haemodialysis for managing severe cardiac failure |
| Q37331943 | Long-term consequences of drugs on the paediatric cardiovascular system |
| Q35562745 | Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers |
| Q37328312 | Mapping genes that contribute to daunorubicin-induced cytotoxicity |
| Q42678363 | Molecular pathogenetic mechanisms and new therapeutic perspectives in anthracycline-induced cardiomyopathy |
| Q55518023 | Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma. |
| Q36015767 | Primary nephrectomy and intraoperative tumor spill: report from the Children's Oncology Group (COG) renal tumors committee |
| Q38732486 | RGD-mediated delivery of small-molecule drugs. |
| Q91975590 | Subclinical Cardiac Dysfunction in Childhood Cancer Survivors on 10-Years Follow-Up Correlates With Cumulative Anthracycline Dose and Is Best Detected by Cardiopulmonary Exercise Testing, Circulating Serum Biomarker, Speckle Tracking Echocardiograph |
| Q92702163 | Synergistic inhibition of tumor cell proliferation by metformin and mito-metformin in the presence of iron chelators |
| Q91607832 | Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree? |
| Q42871448 | Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions |
Search more.